STOCK TITAN
  1. Home
  2. News
  3. PBLA

Panbela Therapeutics Inc. - PBLA STOCK NEWS

Welcome to our dedicated news page for Panbela Therapeutics (Ticker: PBLA), a resource for investors and traders seeking the latest updates and insights on Panbela Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Panbela Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Panbela Therapeutics's position in the market.

News
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Rhea-AI Summary
Panbela Therapeutics, Inc. (PBLA) announces positive clinical data from a Phase 1 study of high dose DFMO treatment in combination with chemotherapy for neuroblastoma patients. The study showed that DFMO treatment was well tolerated, with a median time-to-progression of 19.8 months. The overall objective response rate was 9%, and the progression-free survival at 2 years was 29.5%. These results suggest that CPP-1X is a safe, oral treatment option that may improve response rates in heavily pretreated relapsed refractory neuroblastoma patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1432.26%
Tags
clinical trial
-
News
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
Rhea-AI Summary
Panbela Therapeutics, Inc. (PBLA) announced a 1-for-20 reverse stock split to increase the market price per share and regain compliance with Nasdaq listing requirements. The split will reduce outstanding shares to an estimated 480 thousand and will affect all stockholders uniformly. The company's transfer agent will provide instructions for the exchange of shares, and fractional shares will be paid in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.92%
Tags
stock split
-
News
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) announces agreements with holders of existing warrants to exercise for 2,556,000 shares of common stock, raising approximately $2.0 million. The exercise of new warrants is subject to stockholder approval. The new warrants will be exercisable for up to 5,112,000 shares of common stock at an exercise price of $0.95 per share and will remain exercisable for up to five years after stockholder approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.58%
Tags
none
News
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) announced that US WorldMeds received FDA approval for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma patients. The approval marks the first FDA approval of an NDA for any polyamine targeted therapy in a cancer indication. Panbela divested its pediatric neuroblastoma program to USWM in an arrangement entitling Panbela to up to approximately $9.5 million of non-dilutive funding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
121.01%
Tags
none
-
News
Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) announces the publication of preclinical data from studies of ivospemin and eflornithine research in multiple myeloma. The results demonstrate the anti-neoplastic potential of ivospemin and CPP-1X, offering a compelling rationale for its clinical development as a promising treatment option for multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.36%
Tags
none
-
News
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) receives positive recommendation from the independent Data Safety Monitoring Board (DSMB) for the Phase 3 ASPIRE clinical trial for patients with untreated metastatic pancreatic ductal adenocarcinoma. The DSMB has recommended that the study continue without modification after reviewing safety data for 214 treated patients. The ASPIRE Trial is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. No safety concerns were identified, and the company is looking forward to the interim analysis in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
clinical trial
News
Panbela Provides Business Update and Reports Q3 2023 Financial Results
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) provided a business update and reported financial results for Q3 2023. Recent highlights include collaborations, clinical trial updates, and financial/business developments, such as the divestiture of assets within the pediatric neuroblastoma program to US WorldMeds for an upfront payment of $400,000 and contingent payments totaling up to an additional $9.1 million. The company also announced new patents in China, Chile, and Australia, and a Phase 2 trial in castration resistant metastatic prostate cancer (mCRPC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
earnings
-
News
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
Rhea-AI Summary
Panbela Therapeutics, Inc. has entered into agreements with certain holders of its existing warrants to exercise their warrants at a reduced price of $0.78 per share. The exercise of the warrants is expected to generate approximately $1.9 million in gross proceeds. The new warrants will be exercisable into up to 4,260,000 shares of common stock at an exercise price of $0.78 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.21%
Tags
none
-
News
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
Rhea-AI Summary
Panbela Therapeutics announces the publication of preclinical and clinical data on DFMO treatment in recent onset type 1 diabetes. The data shows that DFMO treatment may preserve β cell function and improve patient outcomes. The Phase 1 clinical study demonstrated that CPP-1X was well tolerated and showed a dose-dependent inhibition of ODC. The study also found that treatment with CPP-1X stabilized C-peptide levels compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.2%
Tags
clinical trial
News
Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
Rhea-AI Summary
Panbela Therapeutics, Inc. has announced the validation of its European patent for a novel process to produce SBP-101, a lead investigational product. The patent, developed in collaboration with Syngene International Ltd., claims a reduced number of synthetic steps from seventeen to six, providing a scalable, efficient, and cost-effective manufacturing process. The patent is valid until 2039.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
none
Stock PBLA logo
Panbela Therapeutics Inc.

Nasdaq:PBLA

PBLA Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

PBLA Stock Data

2.86M
4.85M
0%
0.16%
3.07%
Biotechnology
Healthcare
Link
US
Waconia